GoodRx Holdings, Inc. GDRX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by GoodRx Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: GoodRx Holdings, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about GoodRx Holdings, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is GoodRx Holdings, Inc.'s cash & equivalents?
- GoodRx Holdings, Inc. (GDRX) reported cash & equivalents of $235.71M in Q1 2026.
- How has GoodRx Holdings, Inc.'s cash & equivalents changed year-over-year?
- GoodRx Holdings, Inc.'s cash & equivalents decreased by 21.7% year-over-year, from $300.98M to $235.71M.
- What is the long-term trend for GoodRx Holdings, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), GoodRx Holdings, Inc.'s cash & equivalents has grown at a -23.0% compound annual growth rate (CAGR), from $968.69M to $261.82M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.